Results 61 to 70 of about 11,328,563 (174)
The Journal of Prevention of Alzheimer's DiseaseAlzheimer’s disease (AD) is a growing public health concern in Asia, with an increasing prevalence driven by demographic shifts and rising life expectancy.
So Young Moon +8 more
doaj +1 more source
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract INTRODUCTION Whether glucagon‐like peptide‐1 (GLP‐1) receptor (GLP‐1R) activation lowers Alzheimer's disease (AD) risk via peripheral metabolic improvement or direct neuroprotection remains unclear. METHODS Using blood and brain‐cortex cis‐acting expression quantitative trait loci (cis‐eQTLs) for GLP‐1R as instruments, we performed cis ...
Li Jiang +17 more
wiley +1 more source
The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study [PDF]
, 2017 BACKGROUND: Immunotherapeutic treatments targeting amyloid-β plaques in Alzheimer's disease (AD) are associated with the presence of amyloid-related imaging abnormalities with oedema or effusion (ARIA-E), whose detection and classification is crucial to ...
Ingala, S +11 more
core +1 more source
Proteomic dysregulation associated with cerebral amyloid angiopathy
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract INTRODUCTION Cerebral amyloid angiopathy (CAA) is characterized by impaired vascular amyloid‐β clearance, distinct from Alzheimer's disease (AD), underscoring the need to clarify its molecular basis for predicting therapy‐related amyloid‐related imaging abnormalities. METHODS We analyzed post‐mortem brain proteomics from Religious Orders Study
Sang‐Won Han +8 more
wiley +1 more source
Real‐world implementation of lecanemab in Alzheimer's disease: A Japanese cohort
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease MonitoringINTRODUCTION Real‐world evidence for lecanemab remains limited, particularly among Asian populations. We evaluated the feasibility, safety, biomarker profiles, and short‐term clinical outcomes of lecanemab in practice in Japan.
Sho Shimohama +13 more
doaj +1 more source
Dementia with Lewy bodies and amyloid pathology: Eligible for anti‐amyloid treatment or not?
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract In the future, treatment of dementia will be personalized, targeted to contributing pathologies, rather than the clinical syndrome. Anti‐amyloid drugs for Alzheimer's disease are the first approved drugs; however, the impact of co‑pathology on the treatment effects remains incomplete.
Lieza G Exalto +6 more
wiley +1 more source
Alzheimer’s disease (AD) affects over 6 million people over the age of 65. The advent of new anti-amyloid monoclonal antibodies as treatment for early Alzheimer’s disease these immunotherapeutics may slow disease progression but also pose significant ...
Sarah J. Doran (17812700) +1 more
core +1 more source
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract INTRODUCTION Real‐world data on lecanemab's efficacy and the longitudinal dynamics of plasma biomarkers are scarce in Chinese patients with Alzheimer's disease (AD). METHODS In this multicenter cohort study, 181 AD patients received biweekly lecanemab.
Limoran Tang +33 more
wiley +1 more source
Reply to “CSF Amyloid‐β Risk Stratification in CAA: A Missing Link for Anti‐Amyloid Therapy Safety”
Annals of Neurology, Volume 100, Issue 5, Page 1118-1119, November 2026.
Philipp Arndt, Stefanie Schreiber
wiley +1 more source
Cost‐effectiveness of lecanemab for early Alzheimer's disease in China
Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.Abstract BACKGROUND Although lecanemab has demonstrated clinical efficacy in early Alzheimer's disease (AD), its cost‐effectiveness in China remains uncertain. This study evaluated the long‐term cost‐effectiveness of lecanemab in Chinese patients from a societal perspective and estimated its value‐based price (VBP).
Xingguang Zhao +6 more
wiley +1 more source